Last reviewed · How we verify
Cannabidiol 800
At a glance
| Generic name | Cannabidiol 800 |
|---|---|
| Also known as | CBD |
| Sponsor | Hurd,Yasmin, Ph.D. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Cannabidiol in Opioid Use Disorder and Chronic Pain (EARLY_PHASE1)
- Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa (PHASE2)
- Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI (PHASE2)
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Cannabidiol Medication Intervention Trial (PHASE2)
- SCORE Emerging Adult Cannabis Use & Stress (PHASE1, PHASE2)
- Neuroimaging and CBD for Opioid Use Disorder (PHASE2)
- High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabidiol 800 CI brief — competitive landscape report
- Cannabidiol 800 updates RSS · CI watch RSS
- Hurd,Yasmin, Ph.D. portfolio CI